Global Patient Derived Xenograft Models Market Size (2024 - 2029)

The patient-derived xenograft models market is projected to experience significant growth, driven by an increased focus on cancer research and the development of innovative therapies post-pandemic. The rising incidence of cancer and heightened research and development activities in the pharmaceutical sector, supported by both public and private entities, are key factors contributing to the expansion of this market. Additionally, the growing use of mouse models for cancer drug discovery is expected to further enhance market size. However, challenges such as the high cost of personalized models and stringent regulations regarding animal model usage may hinder market growth.

Market Size of Global Patient Derived Xenograft Models Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Patient Derived Xenograft Models Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 12.50 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration High

Major Players

Patient Derived Xenograft Models Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Patient Derived Xenograft Models Market Analysis

The patient-derived xenograft models market is expected to register a CAGR of 12.5% over the forecast period.

During the COVID-19 pandemic, cancer research was halted as the majority of studies were focused on developing drugs for COVID-19. However, post-pandemic, the majority of the focus of researchers has been on developing innovative therapies for cancer. This is expected to support the growth of the industry.

The rising cases of cancer, rising research and development activities in the pharmaceutical industry, and continuous support for cancer research from the public, as well as the private sector, are the major factors driving the market growth. For instance, according to the GLOBOCAN Report 2020, globally, around 19,292,789 new cancer cases have been reported, and 9,958,133 reported cancer deaths. The majorly affecting cancers are breast cancer, lung cancer, colorectum cancer, and prostate cancer.

In addition, the increasing research using mouse models for drug discovery for cancer is also anticipated to contribute to market growth. For example, as per the article published in April 2022 by Oncoimmunology, the researchers utilized the Diversity Outbred (DO) and Collaborative Cross (CC) mouse models to investigate the outcomes of the immune checkpoint inhibitors (ICI) for a variety of malignancies. The researchers of the study purchased the DO mice models from the Jackson Laboratory and all CC mice from the Systems Genetics Core Facility at the University of North Carolina. Such adoption of mice models in cancer research is expected to contribute to market growth over the forecast period.

However, the high cost of personalized patient-derived xenograft models and stringent regulations towards the use of animal models are likely to impede market growth over the forecast period.

Patient Derived Xenograft Models Industry Segmentation

As per the scope of the report, patient-derived xenografts (PDX) are models in which cancerous tissue from a patient's tumor is implanted directly into humanized mice or rats. The xenograft model offers fast testing of novel compounds on cancer cell lines. The Patient Derived Xenograft Models Market is Segmented By Type (Mice Model, Rats Model), Tumor Type (Gastrointestinal Tumor Model, Gynecological Tumor Model, Respiratory Tumor Model, and Other Tumor Model), End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and Rest of the World). The report offers the value (in USD million) for the above segments.

By Type
Mice Model
Rats Model
By Tumor Type
Gastrointestinal Tumor Model
Gynecological Tumor Model
Respiratory Tumor Model
Other Tumor Model
By End User
Pharmaceutical & Biotechnology Companies
Academic & Research Institutions
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Rest of the World
Need A Different Region Or Segment?
Customize Now

Global Patient Derived Xenograft Models Market Size Summary

The patient-derived xenograft models market is poised for significant growth, driven by the increasing incidence of cancer and heightened research and development activities within the pharmaceutical sector. The focus on innovative cancer therapies has intensified post-COVID-19, as researchers pivot back to cancer studies. This shift is supported by both public and private sector investments, which are crucial in advancing cancer research. The use of mouse models in drug discovery is also contributing to market expansion, as these models offer valuable insights into cancer biology and potential treatments. Despite the promising growth trajectory, challenges such as the high cost of personalized models and stringent regulations on animal use may hinder market progress.

North America is expected to lead the patient-derived xenograft models market, bolstered by rising cancer cases, substantial investments, and the presence of key industry players. The region's growth is further supported by initiatives like the Breast Cancer Society of Canada's funding for precision oncology research. In the United States, advancements in functional precision oncology and strategic partnerships among major players are driving market expansion. The competitive landscape is characterized by a few dominant companies, with strategic agreements and novel research models enhancing their market positions. These factors collectively suggest a robust growth outlook for the market, particularly in North America.

Explore More

Global Patient Derived Xenograft Models Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Cases of Cancer

      2. 1.2.2 Rising R&D Activities in the Pharmaceutical Industry

      3. 1.2.3 Continuous Support for Cancer Research From Public as Well as Private Sector

    3. 1.3 Market Restraints

      1. 1.3.1 High Cost of Personalized Patient Derived Xenograft Models

      2. 1.3.2 Stringent Regulations Towards Use of Animals Models

    4. 1.4 Porter Five Forces

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD Million)

    1. 2.1 By Type

      1. 2.1.1 Mice Model

      2. 2.1.2 Rats Model

    2. 2.2 By Tumor Type

      1. 2.2.1 Gastrointestinal Tumor Model

      2. 2.2.2 Gynecological Tumor Model

      3. 2.2.3 Respiratory Tumor Model

      4. 2.2.4 Other Tumor Model

    3. 2.3 By End User

      1. 2.3.1 Pharmaceutical & Biotechnology Companies

      2. 2.3.2 Academic & Research Institutions

      3. 2.3.3 Others

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Rest of the World

Global Patient Derived Xenograft Models Market Size FAQs

The Global Patient Derived Xenograft Models Market is projected to register a CAGR of 12.5% during the forecast period (2024-2029)

Champions Oncology, Inc., Crown Bioscience, Inc., Charles River Laboratories, Inc., EPO Berlin-Buch GmbH and Oncodesign are the major companies operating in the Global Patient Derived Xenograft Models Market.

Patient Derived Xenograft Models Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)